• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

AREG Gene Record

  • Summary
  • Interactions
  • Claims
  • AREG 374 Druggable GenomeDrug Resistance

    Alternate Names:

    374
    AMPHIREGULIN
    AREG
    AR
    AREGB
    CRDGF
    SDGF
    104640
    651
    ENSG00000109321
    OTTHUMG00000130006
    389
    ENSG00000205595
    PA24933

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (2 More Sources)

    Gene Categories: Category Details

    CELL SURFACE
    GROWTH FACTOR
    DRUG RESISTANCE
    DRUGGABLE GENOME

    Publications:

    Seligmann et al., 2016, Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer., JAMA Oncol
    Sebio A et al., 2014, Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan., Pharmacogenomics J
    Sebio A et al., 2015, EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer., Pharmacogenomics J
    Pentheroudakis et al., 2013, Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes., BMC Cancer
    Sasaki et al., 2011, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors., Cancer Res.
  • PANITUMUMAB   AREG

    Interaction Score: 2.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26867820 23959273


    Sources:
    CIViC PharmGKB

  • CRIZOTINIB   AREG

    Interaction Score: 1.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21791641


    Sources:
    CIViC

  • CETUXIMAB   AREG

    Interaction Score: 1.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23959273 23374602


    Sources:
    CIViC PharmGKB

  • CAPECITABINE   AREG

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25026457


    Sources:
    PharmGKB

  • IRINOTECAN   AREG

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23959273


    Sources:
    PharmGKB

  • Ensembl: ENSG00000109321

    • Version: 101_38

    Alternate Names:
    AREG Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: AREG

    • Version: 18-August-2020

    Alternate Names:
    PA24933 PharmGKB ID

    Gene Info:

    Publications:
    Sebio A et al., 2015, EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer., Pharmacogenomics J
    Sebio A et al., 2014, Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan., Pharmacogenomics J

  • CIViC: AREG

    • Version: 14-September-2020

    Alternate Names:
    374 Entrez Gene ID
    389 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Pentheroudakis et al., 2013, Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes., BMC Cancer
    Seligmann et al., 2016, Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer., JAMA Oncol
    Sasaki et al., 2011, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors., Cancer Res.

  • HingoraniCasas: ENSG00000205595

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000205595 Gene Symbol
    AREGB Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HingoraniCasas: ENSG00000109321

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000109321 Gene Symbol
    AREG Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GO: AREG

    • Version: 01-February-2022

    Alternate Names:
    AREGB GO Gene Synonym
    SDGF GO Gene Synonym

    Gene Info:

    Gene Categories:
    CELL SURFACE, GROWTH FACTOR

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21